KNV1 Gene Association with Disease Potential Drug Targets and Biomarkers

Target Name: KCNV1

NCBI ID: G27012

KCNV1

KNV1 Gene Association with Disease Potential Drug Targets and Biomarkers

KCNV1 (Kv8.1) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. TheKNV1 gene is located on chromosome 8 and encodes a protein that is involved in the regulation of cell growth, differentiation, and survival. TheKNV1 gene has been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Disease-related implication

KCNV1 has been associated with the development and progression of various diseases, including cancer. Studies have shown that individuals with certain genetic variations in theKNV1 gene are at an increased risk of developing cancer. For example, studies have shown that individuals with the SNP rs1805277 are at an increased risk of developing cervical cancer. Additionally, studies have also shown that individuals with the SNP rs1180152 are at an increased risk of developing breast cancer.

Another study has shown that individuals with the SNP rs1767577 are at an increased risk of developing lung cancer. Furthermore, studies have also shown that individuals with the SNP rs2206521 are at an increased risk of developing colorectal cancer.

Potential drug target

KCNV1 has been identified as a potential drug target due to its involvement in the regulation of cell growth and survival. TheKNV1 protein has been shown to play a role in the regulation of cell cycle progression and the control of apoptosis, which are processes that are critical for the development and progression of cancer. Additionally, studies have shown that theKNV1 protein is involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed in the body. This suggests that theKNV1 protein may be a useful target for the development of anti-cancer drugs that target blood vessel formation.

Biomarker potential

KCNV1 has also been identified as a potential biomarker for various diseases, including cancer. Studies have shown that theKNV1 gene has been expressed in various tissues and fluids, including blood, saliva, urine, and tissue samples from cancer patients. Additionally, studies have shown that theKNV1 gene has been associated with the development and progression of various diseases, including cancer. This suggests that theKNV1 gene may be a useful biomarker for the diagnosis and prognosis of cancer.

Methods for identification

To identify potential drug targets and biomarkers for theKNV1 gene, researchers have used a variety of techniques, including genomic and transcriptomic analysis. Genomic analysis involves the analysis of the genetic material of theKNV1 gene to identify any genetic variations that may be associated with the development and progression of diseases. Transcriptomic analysis involves the analysis of the RNA molecules produced by theKNV1 gene to identify any proteins that may be involved in the regulation of cell growth and survival.

Conclusion

In conclusion, theKNV1 gene has been identified as a potential drug target and biomarker for various diseases, including cancer. TheKNV1 protein has been shown to play a role in the regulation of cell cycle progression and the control of apoptosis, which are critical for the development and progression of cancer. Additionally, theKNV1 gene has been associated with the development and progression of various diseases, including cancer. These findings suggest that theKNV1 gene may be a useful target for the development of anti-cancer drugs that target blood vessel formation and the regulation of cell growth and survival. Further research is needed to confirm these findings and to develop effective treatments for theKNV1 gene associated diseases.

Protein Name: Potassium Voltage-gated Channel Modifier Subfamily V Member 1

Functions: Potassium channel subunit that does not form functional channels by itself. Modulates KCNB1 and KCNB2 channel activity by shifting the threshold for inactivation to more negative values and by slowing the rate of inactivation. Can down-regulate the channel activity of KCNB1, KCNB2, KCNC4 and KCND1, possibly by trapping them in intracellular membranes

The "KCNV1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KCNV1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets